HSP90 inhibition as an anticancer strategy: Novel approaches and future directions

Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets

Volumn , Issue , 2009, Pages 111-137

  Powers, Marissa V ^a   Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

17 AAG; Heat shock protein inhibitors; HSP90; siRNA

Indexed keywords

EID: 84889968478     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-8526-0_7     Document Type: Chapter

References (129)

1. Abbas, S., Bhoumik, A., Dahl, R., Vasile, S., Krajewski, S., Cosford, N.D. (2007) Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin Cancer Res, 13, 6769-6778
2. Ali, M.M., Roe, S.M., Vaughan, C.K., Meyer, P., Panaretou, B., Piper, P.W., Prodromou, C., Pearl, L.H. (2006) Crystal structure of an hsp90-nucleotide-p23/sba1 closed chaperone complex. Nature, 440, 1013-1017
3. Argon, Y., Simen, B.B. (1999) GRP94, an ER chaperone with protein and peptide binding properties. Semin Cell Dev Biol, 10, 495-505
4. Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., Seto, E., Bhalla, K. (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem, 280, 26729-26734
5. Banerji, U., Affolter, A., Judson, I., Marais, R., Workman, P. (2008a) BRAF and NRAS mutations in melanoma: Potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther, 7, 737-739
6. Banerji, U., O'Donnell, A., Scurr, M., Pacey, S., Stapleton, S., Asad, Y., Simmons, L., Maloney, A., Raynaud, F., Campbell, M., Walton, M., Lakhani, S., Kaye, S., Workman, P., Judson, I. (2005a) Phase i pharmacokinetic and pharmacodynamic study of 17-Allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol, 23, 4152-4161
7. Banerji, U., Sain, N., Sharp, S.Y., Valenti, M., Asad, Y., Ruddle, R., Raynaud, F., Walton, M., Eccles, S.A., Judson, I., Jackman, A.L., Workman, P. (2008b) An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-Allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother Pharmacol 62(5), 769-78
8. Banerji, U.,Walton, M., Raynaud, F., Grimshaw, R., Kelland, L., Valenti, M., Judson, I.,Workman, P. (2005b) Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-Allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res, 11, 7023-7032
9. Beliakoff, J., Whitesell, L. (2004) Hsp90: An emerging target for breast cancer therapy. Anticancer Drugs, 15, 651-662
10. Bisht, K.S., Bradbury, C.M., Mattson, D., Kaushal, A., Sowers, A., Markovina, S., Ortiz, K.L., Sieck, L.K., Isaacs, J.S., Brechbiel, M.W., Mitchell, J.B., Neckers, L.M., Gius, D. (2003) Geldanamycin and 17-Allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res, 63, 8984-8995
11. Brough, P.A., Aherne, W., Barril, X., Borgognoni, J., Boxall, K., Cansfield, J.E., Cheung, K.M., Collins, I., Davies, N.G., Drysdale, M.J., Dymock, B., Eccles, S.A., Finch, H., Fink, A., Hayes, A., Howes, R., Hubbard, R.E., James, K., Jordan, A.M., Lockie, A., Martins, V., Massey, A., Matthews, T.P., McDonald, E., Northfield, C.J., Pearl, L.H., Prodromou, C., Ray, S., Raynaud, F.I., Roughley, S.D., Sharp, S.Y., Surgenor, A., Walmsley, D.L., Webb, P., Wood, M., Workman, P., Wright, L. (2008) 4, 5-Diarylisoxazole hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer. J Med Chem, 51, 196-218
12. Calderwood, S.K., Khaleque, M.A., Sawyer, D.B., Ciocca, D.R. (2006) Heat shock proteins in cancer: Chaperones of tumorigenesis. Trends Biochem Sci, 31, 164-172
13. Chavany, C., Mimnaugh, E., Miller, P., Bitton, R., Nguyen, P., Trepel, J., Whitesell, L., Schnur, R., Moyer, J., Neckers, L. (1996) P185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J Biol Chem, 271, 4974-4977
14. Chen, B., Piel, W.H., Gui, L., Bruford, E. (2005) The HSP90 family of genes in the human genome: Insights into their divergence and evolution. Genomics, 86, 627-637
15. Chen, S., Smith, D.F. (1998) Hop as an adaptor in the heat shock protein 70(hsp70) and hsp90 chaperone machinery. J Biol Chem, 273, 35194-35200
16. Cheung, K.M.,Matthews, T.P., James, K., Rowlands, M.G., Boxall, K.J., Sharp, S.Y., Maloney, A., Roe, S.M., Prodromou, C., Pearl, L.H., Aherne, G.W., McDonald, E., Workman, P. (2005) The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3, 4-diarylpyrazole class of hsp90 inhibitors. Bioorg Med Chem Lett, 15, 3338-3343
17. Chiosis, G. (2006) Discovery and development of purine-scaffold hsp90 inhibitors. Curr Top Med Chem, 6, 1183-1191
18. Clarke, P.A., Hostein, I., Banerji, U., Stefano, F.D., Maloney, A., Walton, M., Judson, I., Workman, P. (2000) Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-Allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene, 19, 4125-4133
19. Connell, P., Ballinger, C.A., Jiang, J., Wu, Y., Thompson, L.J., Hohfeld, J., Patterson, C. (2001) The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol, 3, 93-96
20. Cortajarena, A.L., Yi, F., Regan, L. (2008) Designed TPR modules as novel anticancer agents. ACS Chem Biol, 3, 161-166
21. da Rocha Dias, S., Friedlos, F., Light, Y., Springer, C., Workman, P., Marais, R. (2005) Activated B-RAF is an hsp90 client protein that is targeted by the anticancer drug 17-Allylamino-17-demethoxygeldanamycin. Cancer Res, 65, 10686-10691
22. Davenport, E.L., Moore, H.E., Dunlop, A.S., Sharp, S.Y., Workman, P., Morgan, G.J., Davies, F.E. (2007) Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood, 110, 2641-2649
23. Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B.A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G.J., Bigner, D.D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J.W., Leung, S.Y., Yuen, S.T., Weber, B.L., Seigler, H.F., Darrow, T.L., Paterson, H., Marais, R., Marshall, C.J., Wooster, R., Stratton, M.R., and Futreal, P.A. (2002) Mutations of the BRAF gene in human cancer. Nature, 417, 949-954
24. Demand, J., Alberti, S., Patterson, C., and Hohfeld, J. (2001) Cooperation of a ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/proteasome coupling. Curr Biol, 11, 1569-1577
25. Dollins, D.E., Immormino, R.M., and Gewirth, D.T. (2005) Structure of unliganded GRP94, the endoplasmic reticulum hsp90. Basis for nucleotide-induced conformational change. J Biol Chem, 280, 30438-30447
26. Dymock, B.W., Barril, X., Brough, P.A., Cansfield, J.E.,Massey, A.,McDonald, E., Hubbard, R.E., Surgenor, A., Roughley, S.D., Webb, P., Workman, P., Wright, L., and Drysdale, M.J. (2005) Novel, potent small-molecule inhibitors of the molecular chaperone hsp90 discovered through structure-based design. J Med Chem, 48, 4212-4215
27. Eccles, S.A., Massey, A., Raynaud, F.I., Sharp, S.Y., Box, G., Valenti, M., Patterson, L., de Haven, B.A., Gowan, S., Boxall, F., Aherne, W., Rowlands, M., Hayes, A.,Martins, V., Urban, F., Boxall, K., Prodromou, C., Pearl, L., James, K., Matthews, T.P., Cheung, K.M., Kalusa, A., Jones, K.,McDonald, E., Barril, X., Brough, P.A., Cansfield, J.E., Dymock, B., Drysdale, M.J., Finch, H., Howes, R., Hubbard, R.E., Surgenor, A.,Webb, P.,Wood, M.,Wright, L., andWorkman, P. (2008) NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res, 68, 2850-2860
28. Edlundh-Rose, E., Egyhazi, S., Omholt, K., Mansson-Brahme, E., Platz, A., Hansson, J., and Lundeberg, J. (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: A study based on mutation screening by pyrosequencing. Melanoma Res, 16, 471-478
29. Egorin, M.J., Rosen, D.M., Wolff, J.H., Callery, P.S., Musser, S.M., and Eiseman, J.L. (1998) Metabolism of 17-(allylamino)-17-demethoxygeldanamycin(NSC 330507) by murine and human hepatic preparations. Cancer Res, 58, 2385-2396
30. Enmon, R., Yang, W.H., Ballangrud, A.M., Solit, D.B., Heller, G., Rosen, N., Scher, H.I., and Sgouros, G. (2003) Combination treatment with 17-N-Allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-Additive growth suppression in human prostate carcinoma spheroids. Cancer Res, 63, 8393-8399
31. Eustace, B.K., Sakurai, T., Stewart, J.K., Yimlamai, D., Unger, C., Zehetmeier, C., Lain, B., Torella, C., Henning, S.W., Beste, G., Scroggins, B.T., Neckers, L., Ilag, L.L., and Jay, D.G. (2004) Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol, 6, 507-514
32. Felts, S.J., Owen, B.A., Nguyen, P., Trepel, J., Donner, D.B., and Toft, D.O. (2000) The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J Biol Chem, 275, 3305-3312
33. Frey, S., Leskovar, A., Reinstein, J., and Buchner, J. (2007) The ATPase cycle of the endoplasmic chaperone grp94. J Biol Chem, 282, 35612-35620
34. Fujiwara, H., Yamakuni, T., Ueno, M., Ishizuka, M., Shinkawa, T., Isobe, T., and Ohizumi, Y. (2004) IC101 induces apoptosis by akt dephosphorylation via an inhibition of heat shock protein 90-ATP binding activity accompanied by preventing the interaction with akt in L1210 cells. J Pharmacol Exp Ther, 310, 1288-1295
35. Gabai, V.L., Budagova, K.R., and Sherman, M.Y. (2005) Increased expression of the major heat shock protein hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. Oncogene, 24, 3328-3338
36. Gallegos Ruiz, M.I., Floor, K., Roepman, P., Rodriguez, J.A., Meijer, G.A., Mooi, W.J., Jassem, E., Niklinski, J., Muley, T., van, Z.N., Smit, E.F., Beebe, K., Neckers, L., Ylstra, B., and Giaccone, G. (2008) Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS ONE, 3, e0001722
37. Goel, V.K., Lazar, A.J., Warneke, C.L., Redston, M.S., and Haluska, F.G. (2006) Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol, 126, 154-160
38. Goetz, M.P., Toft, D., Reid, J., Ames, M., Stensgard, B., Safgren, S., Adjei, A.A., Sloan, J., Atherton, P., Vasile, V., Salazaar, S., Adjei, A., Croghan, G., and Erlichman, C. (2005) Phase i trial of 17-Allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol, 23, 1078-1087
39. Grammatikakis, N., Vultur, A., Ramana, C.V., Siganou, A., Schweinfest, C.W., Watson, D.K., and Raptis, L. (2002) The role of hsp90n, a new member of the hsp90 family, in signal transduction and neoplastic transformation. J Biol Chem, 277, 8312-8320
40. Gray, P.J. Jr., Stevenson, M.A., and Calderwood, S.K. (2007) Targeting cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res, 67, 11942-11950
41. Grbovic, O.M., Basso, A.D., Sawai, A., Ye, Q., Friedlander, P., Solit, D., and Rosen, N. (2006) V600E B-raf requires the hsp90 chaperone for stability and is degraded in response to hsp90 inhibitors. Proc Natl Acad Sci U S A, 103, 57-62
42. Grem, J.L., Morrison, G., Guo, X.D., Agnew, E., Takimoto, C.H., Thomas, R., Szabo, E., Grochow, L., Grollman, F., Hamilton, J.M., Neckers, L., and Wilson, R.H. (2005) Phase i and pharmacologic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol, 23, 1885-1893
43. Gress, T.M., Muller-Pillasch, F.,Weber, C., Lerch, M.M., Friess, H., Buchler, M., Beger, H.G., and Adler, G. (1994) Differential expression of heat shock proteins in pancreatic carcinoma. Cancer Res, 54, 547-551
44. Guo, F., Rocha, K., Bali, P., Pranpat, M., Fiskus, W., Boyapalle, S., Kumaraswamy, S., Balasis, M., Greedy, B., Armitage, E.S., Lawrence, N., and Bhalla, K. (2005) Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-Allylamino-demethoxy geldanamycin. Cancer Res, 65, 10536-10544
45. Gyurkocza, B., Plescia, J., Raskett, C.M., Garlick, D.S., Lowry, P.A., Carter, B.Z., Andreeff, M., Meli, M., Colombo, G., and Altieri, D.C. (2006) Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst, 98, 1068-1077
46. Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. Cell, 100, 57-70
47. Hardcastle, A., Tomlin, P., Norris, C., Richards, J., Cordwell, M., Boxall, K., Rowlands, M., Jones, K., Collins, I., McDonald, E., Workman, P., and Aherne, W. (2007) A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation. Mol Cancer Ther, 6, 1112-1122
48. He, H., Zatorska, D., Kim, J., Aguirre, J., Llauger, L., She, Y.,Wu, N., Immormino, R.M., Gewirth, D.T., and Chiosis, G. (2006) Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J Med Chem, 49, 381-390
49. Hieronymus, H., Lamb, J., Ross, K.N., Peng, X.P., Clement, C., Rodina, A., Nieto, M., Du, J., Stegmaier, K., Raj, S.M., Maloney, K.N., Clardy, J., Hahn, W.C., Chiosis, G., and Golub, T.R. (2006) Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell, 10, 321-330
50. Holmes, J.L., Sharp, S.Y., Hobbs, S., and Workman, P. (2008) Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-Allylamino-17- demethoxygeldanamycin. Cancer Res, 68, 1188-1197
51. Hostein, I., Robertson, D., DiStefano, F., Workman, P., and Clarke, P.A. (2001) Inhibition of signal transduction by the hsp90 inhibitor 17-Allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res, 61, 4003-4009
52. Huang, Y., Zhou, Y., Fan, Y., and Zhou, D. (2008) Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett, 264(1), 101-6
53. Jameel, A., Skilton, R.A., Campbell, T.A., Chander, S.K., Coombes, R.C., and Luqmani, Y.A. (1992) Clinical and biological significance of HSP89 alpha in human breast cancer. Int J Cancer, 50, 409-415
54. Janin, Y.L. (2005) Heat shock protein 90 inhibitors. A text book example of medicinal chemistrý J Med Chem, 48, 7503-7512
55. Jensen, M.R., Schoepfer, J., Radimerski, T., Massey, A., Guy, C.T., Brueggen, J., Quadt, C., Buckler, A., Cozens, R., Drysdale, M.J., Garcia-Echeverria, C., and Chene, P. (2008) NVPAUY922: A small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res, 10, R33
56. Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M.F., Fritz, L.C., and Burrows, F.J. (2003) A high-Affinity conformation of hsp90 confers tumour selectivity on hsp90 inhibitors. Nature, 425, 407-410
57. Kang, B.H., Plescia, J., Dohi, T., Rosa, J., Doxsey, S.J., and Altieri, D.C. (2007) Regulation of tumor cell mitochondrial homeostasis by an organelle-specific hsp90 chaperone network. Cell, 131, 257-270
58. Kasibhatla, S.R., Hong, K., Biamonte, M.A., Busch, D.J., Karjian, P.L., Sensintaffar, J.L., Kamal, A., Lough, R.E., Brekken, J., Lundgren, K., Grecko, R., Timony, G.A., Ran, Y., Mansfield, R., Fritz, L.C., Ulm, E., Burrows, F.J., and Boehm, M.F. (2007) Rationally designed high-Affinity 2-Amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. J Med Chem, 50, 2767-2778
59. Kelland, L.R., Sharp, S.Y., Rogers, P.M., Myers, T.G., and Workman, P. (1999) DT-diaphorase expression and tumor cell sensitivity to 17-Allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst, 91, 1940-1949
60. Kovacs, J.J., Murphy, P.J., Gaillard, S., Zhao, X.,Wu, J.T., Nicchitta, C.V., Yoshida, M., Toft, D.O., Pratt, W.B., and Yao, T.P. (2005) HDAC6 regulates hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell, 18, 601-607
61. Kubota, H., Suzuki, T., Lu, J., Takahashi, S., Sugita, K., Sekiya, S., and Suzuki, N. (2005) Increased expression of GRP94 protein is associated with decreased sensitivity to X-rays in cervical cancer cell lines. Int J Radiat Biol, 81, 701-709
62. Lavictoire, S.J., Parolin, D.A., Klimowicz, A.C., Kelly, J.F., and Lorimer, I.A. (2003) Interaction of hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII. J Biol Chem, 278, 5292-5299
63. Leskovar, A., Wegele, H., Werbeck, N.D., Buchner, J., (2008) The ATPase cycle of the mitochondrial hsp90 analog trap1. J Biol Chem, 283, 11677-11688
64. Majumder, P.K. and Sellers, W.R. (2005) Akt-regulated pathways in prostate cancer. Oncogene, 24, 7465-7474
65. Maloney, A., Clarke, P.A., Naaby-Hansen, S., Stein, R., Koopmann, J.O., Akpan, A., Yang, A., Zvelebil, M., Cramer, R., Stimson, L., Aherne, W., Banerji, U., Judson, I., Sharp, S., Powers, M., deBilly, E., Salmons, J., Walton, M., Burlingame, A., Waterfield, M., and Workman, P. (2007) Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-Allylamino-17-demethoxygeldanamycin. Cancer Res, 67, 3239-3253
66. Marcu, M.G., Chadli, A., Bouhouche, I., Catelli, M., and Neckers, L.M. (2000a) The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem, 275, 37181-37186
67. Marcu, M.G., Schulte, T.W., and Neckers, L. (2000b) Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst, 92, 242-248
68. Martin, C.J., Gaisser, S., Challis, I.R., Carletti, I.,Wilkinson, B., Gregory, M., Prodromou, C., Roe, S.M., Pearl, L.H., Boyd, S.M., and Zhang, M.Q. (2008) Molecular characterization of macbecin as an hsp90 inhibitor. J Med Chem, 51(9), 2853-7
69. Masuda, Y., Shima, G., Aiuchi, T., Horie, M., Hori, K., Nakajo, S., Kajimoto, S., Shibayama-Imazu, T., and Nakaya, K. (2004) Involvement of tumor necrosis factor receptorassociated protein 1(TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin. J Biol Chem, 279, 42503-42515
70. Meli, M., Pennati, M., Curto, M., Daidone, M.G., Plescia, J., Toba, S., Altieri, D.C., Zaffaroni, N., and Colombo, G. (2006) Small-molecule targeting of heat shock protein 90 chaperone function: Rational identification of a new anticancer lead. J Med Chem, 49, 7721-7730
71. Melnick, J., Aviel, S., and Argon, Y. (1992) The endoplasmic reticulum stress protein GRP94, in addition to BiP, associates with unassembled immunoglobulin chains. J Biol Chem, 267, 21303-21306
72. Melnick, J., Dul, J.L., and Argon, Y. (1994) Sequential interaction of the chaperones BiP and GRP94 with immunoglobulin chains in the endoplasmic reticulum. Nature, 370, 373-375
73. Millson, S.H., Truman, A.W., Racz, A., Hu, B., Panaretou, B., Nuttall, J., Mollapour, M., Soti, C., and Piper, P.W. (2007) Expressed as the sole hsp90 of yeast, the alpha and β isoforms of human hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only hsp90β generates sensitivity to the hsp90 inhibitor radicicol. Febs J, 274, 4453-4463
74. Mimnaugh, E.G., Xu, W., Vos, M., Yuan, X., Isaacs, J.S., Bisht, K.S., Gius, D., and Neckers, L. (2004) Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther, 3, 551-566
75. Miyata, Y. and Nishida, E. (2005) CK2 binds, phosphorylates, and regulates its pivotal substrate cdc37, an hsp90-cochaperone. Mol Cell Biochem, 274, 171-179
76. Modi, S., Stopeck, A.T., Gordon, M.S., Mendelson, D., Solit, D.B., Bagatell, R., Ma, W., Wheler, J., Rosen, N., Norton, L., Cropp, G.F., Johnson, R.G., Hannah, A.L., and Hudis, C.A. (2007) Combination of trastuzumab and tanespimycin(17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: A phase i dose-escalation study. J Clin Oncol, 25, 5410-5417
77. Mosser, D.D. and Morimoto, R.I. (2004) Molecular chaperones and the stress of oncogenesis. Oncogene, 23, 2907-2918
78. Munster, P.N., Basso, A., Solit, D., Norton, L., and Rosen, N. (2001) Modulation of hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB-And schedule-dependent manner. See: E. A. Sausville, combining cytotoxics and 17-Allylamino, 17-demethoxygeldanamycin: Sequence and tumor biology matters. Clin Cancer Res, 7, 2155-2158, 2228-2236
79. Neckers, L., Kern, A., and Tsutsumi, S. (2007) Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells. Chem Biol, 14, 1204-1206
80. Pacey, S., Banerji, U., Judson, I., and Workman, P. (2006) Hsp90 inhibitors in the clinic. Handb Exp Pharmacol, 172, 331-358
81. Panaretou, B., Siligardi, G., Meyer, P., Maloney, A., Sullivan, J.K., Singh, S., Millson, S.H., Clarke, P.A., Naaby-Hansen, S., Stein, R., Cramer, R., Mollapour, M.,Workman, P., Piper, P.W., Pearl, L.H., and Prodromou, C. (2002) Activation of the ATPase activity of hsp90 by the stressregulated cochaperone aha1. Mol Cell, 10, 1307-1318
82. Pearl, L.H. (2005) Hsp90 and cdc37-A chaperone cancer conspiracy. Curr Opin Genet Dev, 15, 55-61
83. Pearl, L.H., Prodromou, C., and Workman, P. (2008) The hsp90 molecular chaperone: An open and shut case for treatment. Biochem J, 410, 439-453
84. Pick, E., Kluger, Y., Giltnane, J.M., Moeder, C., Camp, R.L., Rimm, D.L., and Kluger, H.M. (2007) High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res, 67, 2932-2937
85. Plescia, J., Salz, W., Xia, F., Pennati, M., Zaffaroni, N., Daidone, M.G., Meli, M., Dohi, T., Fortugno, P., Nefedova, Y., Gabrilovich, D.I., Colombo, G., and Altieri, D.C. (2005) Rational design of shepherdin, a novel anticancer agent. Cancer Cell, 7, 457-468
86. Powers, M.V. and Workman, P. (2006) Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer, 13(suppl. 1), S125-S135
87. Powers, M.V. and Workman, P. (2007) Inhibitors of the heat shock response: Biology and pharmacology. FEBS Lett, 581, 3758-3769
88. Pridgeon, J.W., Olzmann, J.A., Chin, L.S., and Li, L. (2007) PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol, 5, e172
89. Prodromou, C., Panaretou, B., Chohan, S., Siligardi, G., O'Brien, R., Ladbury, J.E., Roe, S.M., Piper, P.W., and Pearl, L.H. (2000) The ATPase cycle of hsp90 drives a molecular 'clamp' via transient dimerization of the N-Terminal domains. Embo J, 19, 4383-4392
90. Prodromou, C., Roe, S.M., O'Brien, R., Ladbury, J.E., Piper, P.W., and Pearl, L.H. (1997) Identification and structural characterization of the ATP/ADP-binding site in the hsp90 molecular chaperone. Cell, 90, 65-75
91. Radujkovic, A., Schad, M., Topaly, J., Veldwijk, M.R., Laufs, S., Schultheis, B.S., Jauch, A., Melo, J.V., Fruehauf, S., and Zeller, W.J. (2005) Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL-inhibition of P-glycoprotein function by 17-AAG. Leukemia, 19, 1198-1206
92. Rakitina, T.V., Vasilevskaya, I.A., and O'Dwyer, P.J. (2003) Additive interaction of oxaliplatin and 17-Allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling. Cancer Res, 63, 8600-8605
93. Reddy, R.K., Lu, J., and Lee, A.S. (1999) The endoplasmic reticulum chaperone glycoprotein GRP94 with ca(2+)-binding and antiapoptotic properties is a novel proteolytic target of calpain during etoposide-induced apoptosis. J Biol Chem, 274, 28476-28483
94. Reifenberger, J., Knobbe, C.B., Sterzinger, A.A., Blaschke, B., Schulte, K.W., Ruzicka, T., and Reifenberger, G. (2004) Frequent alterations of ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer, 109, 377-384
95. Riggs, D., Cox, M., Cheung-Flynn, J., Prapapanich, V., Carrigan, P., and Smith, D. (2004) Functional specificity of co-chaperone interactions with hsp90 client proteins. Crit Rev Biochem Mol Biol, 39, 279-295
96. Roe, S.M., Ali, M.M., Meyer, P., Vaughan, C.K., Panaretou, B., Piper, P.W., Prodromou, C., and Pearl, L.H. (2004) The mechanism of hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell, 116, 87-98
97. Roe, S.M., Prodromou, C., O'Brien, R., Ladbury, J.E., Piper, P.W., and Pearl, L.H. (1999) Structural basis for inhibition of the hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem, 42, 260-266
98. Sain, N., Krishnan, B., Ormerod, M.G., De, R.A., Liu, W.M., Kaye, S.B., Workman, P., and Jackman, A.L. (2006) Potentiation of paclitaxel activity by the HSP90 inhibitor 17-Allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol Cancer Ther, 5, 1197-1208
99. Sawai, A., Chandarlapaty, S., Greulich, H., Gonen, M., Ye, Q., Arteaga, C.L., Sellers, W., Rosen, N., and Solit, D.B. (2008) Inhibition of hsp90 down-regulates mutant epidermal growth factor receptor(EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res, 68, 589-596
100. Schulte, T.W., Akinaga, S., Soga, S., Sullivan, W., Stensgard, B., Toft, D., and Neckers, L.M. (1998) Antibiotic radicicol binds to the N-Terminal domain of hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones, 3, 100-108
101. Scroggins, B.T., Robzyk, K., Wang, D., Marcu, M.G., Tsutsumi, S., Beebe, K., Cotter, R.J., Felts, S., Toft, D., Karnitz, L., Rosen, N., and Neckers, L. (2007) An acetylation site in the middle domain of hsp90 regulates chaperone function. Mol Cell, 25, 151-159
102. Sharp, S.Y., Boxall, K., Rowlands, M., Prodromou, C., Roe, S.M., Maloney, A., Powers, M., Clarke, P.A., Box, G., Sanderson, S., Patterson, L., Matthews, T.P., Cheung, K.M., Ball, K., Hayes, A., Raynaud, F., Marais, R., Pearl, L., Eccles, S., Aherne, W., McDonald, E., and Workman, P. (2007a) In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res, 67, 2206-2216
103. Sharp, S.Y., Prodromou, C., Boxall, K., Powers, M.V., Holmes, J.L., Box, G., Matthews, T.P., Cheung, K.M., Kalusa, A., James, K., Hayes, A., Hardcastle, A., Dymock, B., Brough, P.A., Barril, X., Cansfield, J.E., Wright, L., Surgenor, A., Foloppe, N., Hubbard, R.E., Aherne, W., Pearl, L., Jones, K., McDonald, E., Raynaud, F., Eccles, S., Drysdale, M., and Workman, P. (2007b) Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther, 6, 1198-1211
104. Shi, Y., Mosser, D.D., and Morimoto, R.I. (1998) Molecular chaperones as HSF1-specific transcriptional repressors. Genes Dev, 12, 654-666
105. Shiau, A.K., Harris, S.F., Southworth, D.R., and Agard, D.A. (2006) Structural analysis of E. Coli hsp90 reveals dramatic nucleotide-dependent conformational rearrangements. Cell, 127, 329-340
106. Smith, D.F., Whitesell, L., Nair, S.C., Chen, S., Prapapanich, V., and Rimerman, R.A. (1995) Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol, 15, 6804-6812
107. Smith, N.F., Hayes, A., James, K., Nutley, B.P., McDonald, E., Henley, A., Dymock, B., Drysdale, M.J., Raynaud, F.I., and Workman, P. (2006) Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors. Mol Cancer Ther, 5, 1628-1637
108. Soga, S., Neckers, L.M., Schulte, T.W., Shiotsu, Y., Akasaka, K., Narumi, H., Agatsuma, T., Ikuina, Y., Murakata, C., Tamaoki, T., and Akinaga, S. (1999) KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of hsp90 binding signaling molecules. Cancer Res, 59, 2931-2938
109. Soga, S., Sharma, S.V., Shiotsu, Y., Shimizu, M., Tahara, H., Yamaguchi, K., Ikuina, Y., Murakata, C., Tamaoki, T., Kurebayashi, J., Schulte, T.W., Neckers, L.M., and Akinaga, S. (2001) Stereospecific antitumor activity of radicicol oxime derivatives. Cancer Chemother Pharmacol, 48, 435-445
110. Solit, D.B., Egorin, M., Valentin, G., Delacruz, A., Ye, Q., Schwartz, L., Larson, S., Rosen, N., and Scher, H.I (2004) Phase 1 pharmacokinetic and pharmacodynamic trial of docetaxel and 17-AAG(17-Allylamino-17- demethoxygeldanamcyin) [abstract 3032]. Proc Am Soc Clin Oncol, 23, 203
111. Solit, D.B. and Rosen, N. (2006) Hsp90: A novel target for cancer therapy. Curr Top Med Chem, 6, 1205-1214
112. Solit, D.B., Zheng, F.F., Drobnjak, M., Munster, P.N., Higgins, B., Verbel, D., Heller, G., Tong, W., Cordon-Cardo, C., Agus, D.B., Scher, H.I., and Rosen, N. (2002) 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res, 8, 986-993
113. Sreedhar, A.S., Kalmar, E., Csermely, P., and Shen, Y.F. (2004a) Hsp90 isoforms: Functions, expression and clinical importance. FEBS Lett, 562, 11-15
114. Sreedhar, A.S., Soti, C., and Csermely, P. (2004b) Inhibition of hsp90: A new strategy for inhibiting protein kinases. Biochim Biophys Acta, 1697, 233-242
115. Stebbins, C.E., Russo, A.A., Schneider, C., Rosen, N., Hartl, F.U., and Pavletich, N.P. (1997) Crystal structure of an hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell, 89, 239-250
116. Supko, J.G., Hickman, R.L., Grever, M.R., and Malspeis, L. (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol, 36, 305-315
117. Suto, R. and Srivastava, P.K. (1995) A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science, 269, 1585-1588
118. Sydor, J.R., Normant, E., Pien, C.S., Porter, J.R., Ge, J., Grenier, L., Pak, R.H., Ali, J.A., Dembski, M.S., Hudak, J., Patterson, J., Penders, C., Pink, M., Read, M.A., Sang, J., Woodward, C., Zhang, Y., Grayzel, D.S., Wright, J., Barrett, J.A., Palombella, V.J., Adams, J., and Tong, J.K. (2006) Development of 17-Allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride(IPI-504), an anti-cancer agent directed against hsp90. Proc Natl Acad Sci U S A, 103, 17408-17413
119. Vasilevskaya, I.A., Rakitina, T.V., and O'Dwyer, P.J. (2003) Geldanamycin and its 17-Allylamino-17-demethoxy analogue antagonize the action of cisplatin in human colon adenocarcinoma cells: Differential caspase activation as a basis for interaction. Cancer Res, 63, 3241-3246
120. Vasilevskaya, I.A., Rakitina, T.V., and O'Dwyer, P.J. (2004) Quantitative effects on c-Jun N-Terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-Allylamino-17-demethoxygeldanamycin in colon cancer cell lines. Mol Pharmacol, 65, 235-243
121. Wanderling, S., Simen, B.B., Ostrovsky, O., Ahmed, N.T., Vogen, S.M., Gidalevitz, T., and Argon, Y. (2007) GRP94 is essential for mesoderm induction and muscle development because it regulates insulin-like growth factor secretion. Mol Biol Cell, 18, 3764-3775
122. Wandinger, S.K., Suhre, M.H., Wegele, H., and Buchner, J. (2006) The phosphatase ppt1 is a dedicated regulator of the molecular chaperone hsp90. Embo J, 25, 367-376
123. Wegele, H., Muller, L., and Buchner, J. (2004) Hsp70 and hsp90-A relay team for protein folding. Rev Physiol Biochem Pharmacol, 151, 1-44
124. Wright, L., Barril, X., Dymock, B., Sheridan, L., Surgenor, A., Beswick, M., Drysdale, M., Collier, A., Massey, A., Davies, N., Fink, A., Fromont, C., Aherne, W., Boxall, K., Sharp, S., Workman, P., and Hubbard, R.E. (2004) Structure-Activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem Biol, 11, 775-785
125. Xu, W., Soga, S., Beebe, K., Lee, M.J., Kim, Y.S., Trepel, J., and Neckers, L. (2007) Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to hsp90 inhibition. Br J Cancer, 97, 741-744
126. Yang, H., Chen, D., Cui, Q.C., Yuan, X., and Dou, Q.P. (2006) Celastrol, a triterpene extracted from the chinese thunder of god vine, is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res, 66, 4758-4765
127. Young, J.C., Agashe, V.R., Siegers, K., and Hartl, F.U. (2004) Pathways of chaperone-mediated protein folding in the cytosol. Nat Rev Mol Cell Biol, 5, 781-791
128. Zhang, T., Hamza, A., Cao, X., Wang, B., Yu, S., Zhan, C.G., and Sun, D. (2008) A novel hsp90 inhibitor to disrupt hsp90/cdc37 complex against pancreatic cancer cells. Mol Cancer Ther, 7, 162-170
129. Zhao, Y.G., Gilmore, R., Leone, G., Coffey, M.C., Weber, B., and Lee, P.W. (2001) Hsp90 phosphorylation is linked to its chaperoning function.